The Bizarre Biological Trick That Makes Mollusk Teeth Tougher Than Steel
A new study published August 7 in Science presents a detailed investigation into what makes chiton teeth so strong and durable. By analyzing chiton anatomy, the team found a remarkably precise, consistent stream of iron-binding proteins that resulted in dental structures 'superior to materials used in industrial cutting tools, grinding media, dental implants, surgical implants, and protective coatings,' paper co-author David Kisalilus explained in a statement. Even more impressive is the fact that, unlike human-made materials, chitons produce their teeth at room temperature with nanoscale precision, he added.
The new paper lays out the underlying mechanisms of this process, which the researchers believe could inform future advances in the fabrication of advanced materials. 'We can learn a lot from these biological designs and processes,' said Kisalius, a materials scientist at the University of California.
Kisalius collaborated with research partners in Japan to study larger types of chitons found in the northwest United States and the coasts of Hokkaido, Japan. They identified a protein, RTMP1, which is unique to chitons and enables the deposition of iron onto the mollusks' teeth. Scientists knew that this allowed chitons to scrape off stubborn bits of algae from rock, but it was unknown how and when these proteins interacted with chiton teeth.
Using tools from both material science and molecular biology, the researchers built the protein's itinerary through chiton anatomy 'from the ground up,' Kisalilus explained. First, RTMP1 travels through nanoscopic tubes leading out from each tooth, then binds to compounds that control the architecture of magnetite, a type of iron oxide. At the same time, the protein releases the iron stored in ferritin, another protein found in the tissues near chiton teeth. As a result, the new teeth grow into neat rows of ultrahard structures that also grow back after a certain amount of wear.
The results demonstrate a fantastic opportunity for humans to learn from nature. Further investigations into chiton teeth could inform 'spatially and temporally controlled synthesis of other materials for a broad range of applications, such as batteries, fuel cell catalysts, and semiconductors,' Kisailus said, in addition to 'new approaches toward additive manufacturing—3D printing—and synthesis methods that are far more environmentally friendly and sustainable.'
Those are perhaps grand expectations for a creature as visually unassuming as the chiton. Then again, these mollusks look extra metal when flipped over (both literally and figuratively). So who knows? Maybe chiton dental steel will truly be the next big thing in materials science.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
AI designs antibiotics for gonorrhoea and MRSA superbugs
Artificial intelligence has invented two new potential antibiotics that could kill drug-resistant gonorrhoea and MRSA, researchers have revealed. The drugs were designed atom-by-atom by the AI and killed the superbugs in laboratory and animal tests. The two compounds still need years of refinement and clinical trials before they could be prescribed. But the Massachusetts Institute of Technology (MIT) team behind it say AI could start a "second golden age" in antibiotic discovery. Antibiotics kill bacteria, but infections that resist treatment are now causing more than a million deaths a year. Overusing antibiotics has helped bacteria evolve to dodge the drugs' effects, and there has been a shortage of new antibiotics for decades. Researchers have previously used AI to trawl through thousands of known chemicals in an attempt to identify ones with potential to become new antibiotics. New superbug-killing antibiotic discovered using AI Now, the MIT team have gone one step further by using generative AI to design antibiotics in the first place for the sexually transmitted infection gonorrhoea and for potentially-deadly MRSA (methicillin-resistant Staphylococcus aureus). Their study, published in the journal Cell, interrogated 36 million compounds including those that either do not exist or have not yet been discovered. Scientists trained the AI by giving it the chemical structure of known compounds alongside data on whether they slow the growth of different species of bacteria. The AI then learns how bacteria are affected by different molecular structures, built of atoms such as carbon, oxygen, hydrogen and nitrogen. Two approaches were then tried to design new antibiotics with AI. The first identified a promising starting point by searching through a library of millions of chemical fragments, eight to 19 atoms in size, and built from there. The second gave the AI free reign from the start. The design process also weeded out anything that looked too similar to current antibiotics. It also tried to ensure they were inventing medicines rather than soap and to filter out anything predicted to be toxic to humans. Scientists used AI to create antibiotics for gonorrhoea and MRSA, a type of bacteria that lives harmlessly on the skin but can cause a serious infection if it enters the body. Once manufactured, the leading designs were tested on bacteria in the lab and on infected mice, resulting in two new potential drugs. "We're excited because we show that generative AI can be used to design completely new antibiotics," Prof James Collins, from MIT, tells the BBC. "AI can enable us to come up with molecules, cheaply and quickly and in this way, expand our arsenal, and really give us a leg up in the battle of our wits against the genes of superbugs." However, they are not ready for clinical trials and the drugs will require refinement – estimated to take another one to two year's work – before the long process of testing them in people could begin. I found a bacteria-eating virus in my loo - could it save your life? Dr Andrew Edwards, from the Fleming Initiative and Imperial College London, said the work was "very significant" with "enormous potential" because it "demonstrates a novel approach to identifying new antibiotics". But he added: "While AI promises to dramatically improve drug discovery and development, we still need to do the hard yards when it comes to testing safety and efficacy." That can be a long and expensive process with no guarantee that the experimental medicines will be prescribed to patients at the end. Some are calling for AI drug discovery more broadly to improve. Prof Collins says "we need better models" that move beyond how well the drugs perform in the laboratory to ones that are a better predictor of their effectiveness in the body. There is also an issue with how challenging the AI-designs are to manufacture. Of the top 80 gonorrhoea treatments designed in theory, only two were synthesised to create medicines. Prof Chris Dowson, at the University of Warwick, said the study was "cool" and showed AI was a "significant step forward as a tool for antibiotic discovery to mitigate against the emergence of resistance". However, he explains, there is also an economic problem factoring into drug-resistant infections - "how do you make drugs that have no commercial value?" If a new antibiotic was invented, then ideally you would use it as little as possible to preserve its effectiveness, making it hard for anyone to turn a profit.
Yahoo
an hour ago
- Yahoo
We weren't actually more anxious during Covid, researchers discover
You weren't actually more anxious during the Covid pandemic. Scientists say that anxiety levels among U.S. adults appear to have stayed steady during that period, with new research challenging the belief that there was a widespread spike in psychological distress. Previous research had found a 25 percent increase in the prevalence of anxiety and depression, which the World Health Organization said was linked to feelings of loneliness and fear of infection during the pandemic. The new research, which surveyed nearly 100,000 U.S. adults between 2011 and 2022, found that there was no prolonged spike in anxiety levels for younger or older adults. 'Our results might suggest that the mental health of U.S. adults is more resilient than public perception suggests, given the many news headlines about the U.S. currently experiencing a 'mental health crisis,'' Noah French, a researcher at University of Virginia and an author of the new study, explained in a statement. The pandemic was cited by Biden administration officials as worsening America's mental health crisis in 2023, and the Centers for Disease Control and Prevention now says nearly one in four U.S. adults report having a mental illness. Some 38 percent more people had been in mental health care since the onset of the pandemic, researchers said. The pandemic disproportionately affected the mental health of younger adults, WHO has reported. The isolating impact of school closures also resulted in anxious kids who were academically behind their peers, according to an analysis in The New York Times, and dozens of related studies. However, the new study found that while those aged 18-25 showed significantly stronger symptoms of anxiety compared to older adults during the pandemic, young adults' anxiety levels did not increase from 2011 to 2022 overall. The reasons behind these observations in younger and older adults are unclear. Other surveys have found that Americans are feeling more anxious in general. Polling data from last year found that 43 percent of U.S. adults felt more anxious than they did the previous year and in 2022, according to the American Psychiatric Association. This uptick in American anxiety stems from current events, the economy, and gun violence, the association said. And of the more than 2,200 adults surveyed, 63 percent said they were anxious about their health. It's also possible that worsening mental health was the reason Americans drank more alcohol during the pandemic, according to doctors. One study suggested that mothers with young children drank 300 percent more alcohol than they did before Covid. French said that more research is needed to fully understand what happened, and cautioned against drawing firm conclusions on anxiety levels from his findings. For one, participants skewed younger, were more educated, and had all signed up to answer the questions. That means that they might not be entirely representative of the average American. 'One of my biggest personal takeaways from this project is that there is surprisingly little high-quality research tracking the mental health of entire populations over time,' French said. 'We need a lot more research in this space, and I will forever be skeptical of headlines that make strong claims about a certain mental health condition being 'on the rise.''
Medscape
an hour ago
- Medscape
Raynaud Phenomenon Tied to Elevated Cardiovascular Risk
TOPLINE: Individuals with Raynaud phenomenon without underlying systemic autoimmune rheumatic diseases had higher risks for major adverse cardiovascular events (MACE) and venous thromboembolism than did a comparator group with irritable bowel syndrome (IBS), regardless of age. METHODOLOGY: Researchers conducted a retrospective cohort study to examine whether individuals with Raynaud phenomenon experienced cardiovascular outcomes more frequently than those without the condition. They included 30,088 individuals younger than 45 years and 60,145 aged 45 years or older with Raynaud phenomenon without systemic autoimmune rheumatic diseases , identified from electronic health records of centers in North America between March 2005 and March 2025. An equal number of propensity score-matched individuals with IBS were assigned as comparators to both age categories. The researchers chose IBS as a comparator group because, like Reynaud phenomenon, it is common in younger and female individuals. In addition, it is not known to be associated with adverse cardiovascular outcomes. Co-primary outcomes were MACE and venous thromboembolism, evaluated over mean follow-up durations of 4.4-4.9 years across groups. TAKEAWAY: Among individuals younger than 45 years, those with Raynaud phenomenon had higher risks for MACE (hazard ratio [HR], 1.23; 95% CI, 1.07-1.42) and venous thromboembolism (HR, 1.32; 95% CI, 1.20-1.46) than did those with IBS. Similar results were observed among individuals aged 45 years or older, where those with Raynaud phenomenon had higher risks for MACE (HR, 1.17; 95% CI, 1.13-1.20) and venous thromboembolism (HR, 1.20; 95% CI, 1.14-1.26) than those with IBS. Individuals with Raynaud phenomenon had higher risks for secondary outcomes such as stroke, any cardiovascular disease, and pulmonary embolism noted in both age categories. IN PRACTICE: '[This] data substantiates several previous reports of an increased risk of CVD [cardiovascular disease] in individuals with RP [Raynaud phenomenon], and provides further supporting evidence of a similar risk of VTE [venous thromboembolism],' the authors of the study wrote. 'Taken together our findings lend further support to suggest that RP (in the absence of any secondary SARD [systemic autoimmune rheumatic disease]) could be a manifestation of subclinical CVD. Of course, this requires further confirmation including prospective studies,' they added. SOURCE: This study was led by Michael Hughes, The University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom. It was published online on August 5, 2025, in Seminars in Arthritis and Rheumatism. LIMITATIONS: Diagnostic codes were used for identifying the conditions; however, misclassification bias may be possible. Details such as digital ischemic episodes were not available for individuals with Raynaud phenomenon and age of onset and family history were not assessed. Many oral drug treatments for Raynaud phenomenon are vasodilators also used for systemic hypertension; hence, the primary indication was unclear. DISCLOSURES: One author reported receiving support from the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre. Another author reported receiving support from NIHR Clinical Lectureship, and working at centers supported by Versus Arthritis and NIHR Manchester Biomedical Research Centre. Two authors reported receiving research funding, speaker fees, honoraria, and consultancy fees and having other financial ties with multiple companies including Janssen, Sanofi, and Novartis. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
